These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ellagic acid reveals promising anti-aging effects against d-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: A mechanistic study.
    Author: Rahimi VB, Askari VR, Mousavi SH.
    Journal: Biomed Pharmacother; 2018 Dec; 108():1712-1724. PubMed ID: 30372874.
    Abstract:
    BACKGROUND: Aging is a progressive, accumulative and natural phenomenon that leads to irreversible changes in all molecules, cells, tissues and organs of an organism. Previous studies have demonstrated that d-galactose (DG) imitates human natural aging. EA has also shown many pharmacological properties including anti-inflammatory and anti-oxidant activities. METHODS: In the present study, we are aimed to evaluate anti-aging effects of EA (0.01-10 μM) on DG-induced aging model in SH-SY5Y human neuroblastoma cells, using assessment of cell proliferation, lipid peroxidation (MDA), intra-cellular reactive oxygen species (ROS), inflammation (TNF-α), total glutathione content (GSH), Beta-Galactosidase (β-GAL) and advanced glycation end products (AGEs) levels. Furthermore, the effects of EA were examined on HO-1 or PPAR-γ pathways using their selective inhibitors ZnPP or GW9662, respectively. RESULTS: The results revealed that EA (0.01-10 μM) significantly increased cell proliferation and GSH level, while decreased the levels of ROS, MDA, TNF-α, β-GAL and AGEs following DG-induced aging. Our findings also presented that pre-incubation with ZnPP exacerbates toxicity features of DG-induced aging in all measured parameters. Furthermore, we showed that pre-incubation of EA (0.1 and 1 μM) with either GW9662 or ZnPP significantly prevents the protective activities on cell proliferation, ROS, MDA, GSH and TNF-α levels following DG-induced aging (p < 0.001 for all cases). Additionally, EA (0.1 and 1 μM) along with GW9662 did not affect the levels of β-GAL and AGES in comparison to DG-induced aging group. CONCLUSION: Although we described for the first time that EA at low concentrations (0.1-1 μM) provides greater antiaging properties than both its high concentration (10 μM) and metformin (2.5 mM) probably through PPAR-γ/HO-1 signaling pathway, but additional and deeper investigations are needed to show exact involving mechanisms. It could be suggestible that EA may be as anti-aging agent at low concentrations for age-related neurological disorders such as Parkinson's and Alzheimer's diseases.
    [Abstract] [Full Text] [Related] [New Search]